Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Relay Therapeutics (RLAY) is back in focus after reporting a narrower than expected quarterly loss, higher year on year revenue, and securing FDA Breakthrough Therapy designation for its zovegalisib program in oncology. See our latest analysis for Relay Therapeutics. That backdrop has attracted fresh attention to the stock, with a 1 day share price return of 12.01% and a 30 day share price return of 34.12%. The 1 year total shareholder return is very large compared to its 3 and 5 year total shareholder return declines, hinting that recent earnings, FDA Breakthrough Therapy designation and upcoming data updates have shifted how investors are weighing Relay Therapeutics' risks and potential. If this kind of move in Relay Therapeutics has you looking across the sector, it could be a good moment to check out 27 healthcare AI stocks as a starting list of other names to research. With the shares up sharply, a 1 year total return that is very large, and the last close of US$10.26 si
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $13.00 to $15.00. They now have an "overweight" rating on the stock.MarketBeat
- Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 MilestonesGlobeNewswire
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences in MarchGlobeNewswire
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- RLAY's page on the SEC website